SCHEMBL2515684

SCHEMBL2515684

O=C(O)c1cc(C(F)(F)F)cc(Cl)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.46
SORT1 Q99523 1/20 0.46
HPGD P15428 4/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MRGPRX4 Q96LA9 5/20 0.43
RXRA P19793 2/20 0.42
RXRB P28702 2/20 0.42
TSHR P16473 2/20 0.42
CES2 O00748 1/20 0.41
RXRG P48443 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 2/20 0.40
MEN1 O00255 1/20 0.40
TTR P02766 1/20 0.40
PPOX P50336 1/20 0.40
KMT2A Q03164 1/20 0.40
GLA P06280 1/20 0.40
GRIK1 P39086 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27816993 0.85 GPR35 (0.42) GPR35SORT1HPGDALDH1A1TSHR
SCHEMBL43365 0.83 MRGPRX4 (0.46) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL27887866 0.83 RXRA (0.53) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL7928555 0.83 CES2 (0.46) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL24973075 0.81 MRGPRX4 (0.45) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL31129189 0.81 MRGPRX4 (0.45) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL16529671 0.81 KDM4E (0.50) GPR35SORT1HPGDALDH1A1KDM4E
SCHEMBL13955645 0.81 CYP3A4 (0.59) GPR35SORT1HPGDALDH1A1KDM4E
Hydrochloric Acid SCHEMBL42961 0.81 MRGPRX4 (0.45) GPR35SORT1HPGDALDH1A1KDM4E
Hydrochloric Acid SCHEMBL11625860 0.80 ALDH1A1 (0.49) GPR35SORT1HPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273741-B2 Imidazo-pyridazinyl compounds and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-09-25 US disclosed
US-8044049-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-25 US disclosed
US-8034812-B2 Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-11 US disclosed
US-20100273788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-28 US disclosed
US-20100168424-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-01 US disclosed
US-20090306374-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed
US-20090137595-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed
EP-2049541-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-04-22 EP disclosed
WO-2008016192-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-07 WO disclosed
EP-0847977-B1 2,3-DIHALOGENO-6-TRIFLUOROMETHYLBENZENE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME NIPPON SODA CO (JP) 2001-08-29 EP disclosed
US-6054624-A USEFUL AS THE STARTING MATERIALS FOR PRODUCING PESTICIDES, DRUGS AND THE LIKE NIPPON SODA CO., LTD. (JP) 2000-04-25 US disclosed
US-6054605-A CHEMICAL INTERMEDIATE FOR DRUGS, PESTICIDES NIPPON SODA CO., LTD. (JP) 2000-04-25 US disclosed
EP-0847977-A1 2,3-DIHALOGENO-6-TRIFLUOROMETHYLBENZENE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME NIPPON SODA CO., LTD. (JP) 1998-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF KDR, FLT1, FLT4 GPR35 1918/4885SORT1 2841/4885HPGD 475/4885
US-20090137595-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF KDR, FLT1, FLT4 GPR35 1918/4885SORT1 2841/4885HPGD 475/4885
US-20090306374-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF KDR, FLT1, FLT4 GPR35 1918/4885SORT1 2841/4885HPGD 475/4885
US-20100168424-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF KDR, FLT1, FLT4 GPR35 1831/4885SORT1 3115/4885HPGD 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.